Citizens Jmp Lowers GH Research (NASDAQ:GHRS) Price Target to $39.00

GH Research (NASDAQ:GHRS) had its price objective reduced by research analysts at Citizens Jmp from $42.00 to $39.00 in a research note issued on Friday,Benzinga reports. The firm presently has a “market outperform” rating on the stock. Citizens Jmp’s price objective suggests a potential upside of 75.60% from the stock’s current price.

A number of other brokerages have also commented on GHRS. Weiss Ratings reiterated a “sell (d-)” rating on shares of GH Research in a report on Tuesday, April 21st. Needham & Company LLC boosted their price objective on shares of GH Research from $31.00 to $32.00 and gave the stock a “buy” rating in a report on Friday, March 6th. Royal Bank Of Canada boosted their price objective on shares of GH Research from $33.00 to $40.00 and gave the stock an “outperform” rating in a report on Friday, January 23rd. Citigroup reiterated an “outperform” rating on shares of GH Research in a report on Friday. Finally, Guggenheim set a $34.00 price objective on shares of GH Research and gave the stock a “buy” rating in a report on Tuesday, March 10th. Nine analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $39.75.

GH Research Stock Performance

GH Research stock opened at $22.21 on Friday. The stock’s 50 day moving average price is $17.03 and its 200 day moving average price is $15.49. The firm has a market capitalization of $1.38 billion, a PE ratio of -27.76 and a beta of 1.27. GH Research has a one year low of $9.52 and a one year high of $24.66.

GH Research (NASDAQ:GHRS) last released its quarterly earnings results on Thursday, May 14th. The company reported ($0.31) EPS for the quarter, missing the consensus estimate of ($0.27) by ($0.04). On average, analysts forecast that GH Research will post -1.52 earnings per share for the current fiscal year.

Hedge Funds Weigh In On GH Research

A number of institutional investors have recently made changes to their positions in the business. Barclays PLC raised its stake in shares of GH Research by 63.4% in the 4th quarter. Barclays PLC now owns 2,118 shares of the company’s stock valued at $27,000 after purchasing an additional 822 shares in the last quarter. North Star Investment Management Corp. acquired a new stake in shares of GH Research in the 1st quarter valued at about $31,000. Mirae Asset Global Investments Co. Ltd. acquired a new stake in shares of GH Research in the 4th quarter valued at about $38,000. Osaic Holdings Inc. raised its stake in shares of GH Research by 63.6% in the 2nd quarter. Osaic Holdings Inc. now owns 6,175 shares of the company’s stock valued at $75,000 after purchasing an additional 2,400 shares in the last quarter. Finally, JPMorgan Chase & Co. acquired a new stake in shares of GH Research in the 2nd quarter valued at about $79,000. 56.90% of the stock is owned by institutional investors and hedge funds.

About GH Research

GH Research Holdings Inc is a clinical-stage biotechnology company dedicated to the development of novel treatments for neuropsychiatric disorders through the application of psychedelic-inspired compounds. Headquartered in Dublin, Ireland, the company focuses on harnessing the unique pharmacology of 5-methoxy-N-dimethyltryptamine (5-MeO-DMT) and related molecules to address high unmet medical needs in mental health.

The firm’s lead program, GH001, is an inhaled formulation of 5-MeO-DMT that has completed early-stage clinical trials assessing safety, tolerability and preliminary efficacy in treatment-resistant depression.